PerkinElmer recently declared the launch of the HER2Sense preclinical imaging agent that will allow personalized medicine approach for breast cancer study. The HER2Sense agent is the first fluorescent imaging agent that utilizes a commercially-available therapeutic antibody to facilitate various research applications.
Popular as an antibody-based optical probe that supports various researches, this HER2Sense agent’s therapeutic significance is based on Trastuzumab therapeutic antibody that is capable of detecting the HER2/Neu receptor for treating diverse cancer types. Trastuzumab has originated from Roche Custom Biotech. PerkinElmer’s proprietary VivoTag fluorescent dye has been incorporated in the HER2Sense agent for more effective performance.
The therapeutic-featured HER2Sense agent has been considered by researchers as an ideal tool for analyzing the mechanisms of disease, due to its efficiency in providing personalized medicine. In recent years, personalized diagnostic methods have been considered as the most effective strategy in treating breast cancer. Furthermore, it has been observed that modulating and targeting HER2’s function seems to ensure its use as an effective therapeutic tool. By integrating the Trastuzumab in clinical settings with the therapeutic advantages of HER2Sense agent in preclinical research, a clear perceptive of the disease model can be achieved.
Since rastuzumab is capable of specifically detecting the HER2/Neu receptor. the HER2Sense agent can be employed to examine the status of the HER2/Neu receptor in non-breast cancer models in living systems. The HER2Sense agent’s high sensitivity evades the systemic immune response existing in other antibody-based imaging agents that were involved in discovery research.
Source: http://www.perkinelmer.com/